US2018222955A1PendingUtilityA1
Gene therapy for diabetic neuropathy using an hgf isoform
Est. expiryNov 3, 2031(~5.3 yrs left)· nominal 20-yr term from priority
A61K 31/711A61K 38/1833C07K 14/4753A61K 48/005A61P 3/10
66
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetic neuropathy, wherein the pharmaceutical composition comprises, as active ingredients, different types of isoforms of HGF or a polynucleotide encoding the isoforms. The present invention is the first invention demonstrating that diabetic neuropathy can be prevented and treated using different types of isoforms of HGF. According to the present invention, it is possible to very effectively treat diabetic neuropathy.
Claims
exact text as granted — not AI-modified1 . A pharmaceutical composition for the prevention or treatment of diabetic neuropathy, the composition comprising, as active ingredients, different types of isoforms of hepatocyte growth factor (HGF) or at least one polynucleotide encoding the isoforms.
Join the waitlist — get patent alerts
Track US2018222955A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.